Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart, Anlotinib, and Cyclophosphamide in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07489300Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 2 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07489300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489300.